• Altimmune posted a net loss of USD 22.8 million, or USD 0.12 a share, for the quarter ended June 30, 2026.
• R&D expense rose to USD 18.7 million from USD 17.2 million a year earlier, due to ALD trial activity and PERFORMA Phase 3 startup costs.
• G&A expense increased to USD 7.6 million from USD 5.7 million on higher professional services and compensation.
• Cash, cash equivalents and investments totaled USD 519 million as of June 30, 2026.
• Initiated the PERFORMA Phase 3 MASH trial; 52-week data readout anticipated in 2029.
• RECLAIM Phase 2 AUD trial met its primary endpoint; RESTORE Phase 2 ALD enrollment completed with topline data expected in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9808323) on August 12, 2026, and is solely responsible for the information contained therein.